News
2 minute read

MBHB Partner Kevin Noonan Quoted in Bio-Pharma Reporter Article Entitled, "All indications? Newer biosimilars may prompt US FDA extrapolation rethink says expert"

Kevin E. Noonan, Ph.D.January 29, 2016

McDonnell Boehnen Hulbert & Berghoff LLP partner Dr. Kevin Noonan is quoted in a January 29, 2016 online edition of BioPharmaReporter.com in an article entitled, “All indications? Newer biosimilars may prompt US FDA extrapolation rethink says expert.” While data extrapolation is acceptable in approving US biosimilars across the same indications as its reference, the practice will not be applicable for the next generation of copycat biologics, a biotech expert says. View the article